SILO PHARMA, INC. Sale of Stock, Consideration Received on Transaction
SILO PHARMA, INC. (SILO) reported Sale of Stock, Consideration Received on Transaction of $714.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Equity
us-gaap:SaleOfStockConsiderationReceivedOnTransaction · last filed 2026-08-13
- SILO PHARMA, INC. sale of stock, consideration received on transaction for the quarter ending 2026-06-30 was $0.00.
- SILO PHARMA, INC. sale of stock, consideration received on transaction for the quarter ending 2026-03-31 was $714.00K.
- SILO PHARMA, INC. sale of stock, consideration received on transaction for fiscal 2021 was $7.02M.
| Period end | Sale of Stock, Consideration Received on Transaction | Sale of Stock, Consideration Received on Transaction 0 month | Sale of Stock, Consideration Received on Transaction 1 month | Sale of Stock, Consideration Received on Transaction 3 month | Sale of Stock, Consideration Received on Transaction 6 month | Sale of Stock, Consideration Received on Transaction 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $714.00K 10-Q · filed 2026-08-13 | ||||
| 2026-03-31 | $714.00K 10-Q · filed 2026-05-14 | |||||
| 2021-12-31 | $7.02M 10-K · filed 2022-03-28 | |||||
| 2021-02-09 | $4.28M 10-Q · filed 2021-11-10 | |||||
| 2020-04-28 | $2.40M 10-Q · filed 2020-11-05 | $2.40M 10-K/A · filed 2021-05-17 | ||||
| 2020-04-18 | $75.64K 10-K/A · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |